Stimulation of prostate cancer cellular proliferation and invasion by the androgen receptor co-activator ARA70.

Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk. Hum Mol Genet (2009) 1.90

Mifepristone inhibits GRβ coupled prostate cancer cell proliferation. J Urol (2012) 1.51

Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet (2010) 1.40

Tumor suppressor function of androgen receptor coactivator ARA70alpha in prostate cancer. Am J Pathol (2010) 1.02

Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J Transl Res (2009) 0.99

Protein arginine methyltransferase 5 functions in opposite ways in the cytoplasm and nucleus of prostate cancer cells. PLoS One (2012) 0.98

TBLR1 as an androgen receptor (AR) coactivator selectively activates AR target genes to inhibit prostate cancer growth. Endocr Relat Cancer (2014) 0.92

Investigation of the relationship between prostate cancer and MSMB and NCOA4 genetic variants and protein expression. Hum Mutat (2012) 0.89

Comprehensive resequence analysis of a 97 kb region of chromosome 10q11.2 containing the MSMB gene associated with prostate cancer. Hum Genet (2009) 0.88

Promoter variants in the MSMB gene associated with prostate cancer regulate MSMB/NCOA4 fusion transcripts. Hum Genet (2012) 0.88

Gene expression profiles of human glioblastomas are associated with both tumor cytogenetics and histopathology. Neuro Oncol (2010) 0.86

Androgen-induced activation of gonadotropin-regulated testicular RNA helicase (GRTH/Ddx25) transcription: essential role of a nonclassical androgen response element half-site. Mol Cell Biol (2012) 0.84

The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy. Curr Drug Targets (2013) 0.80

Expression and function of nuclear receptor co-activator 4: evidence of a potential role independent of co-activator activity. Cell Mol Life Sci (2012) 0.79

Role of androgen and vitamin D receptors in endothelial cells from benign and malignant human prostate. Am J Physiol Endocrinol Metab (2013) 0.79

Androgen receptor coactivators that inhibit prostate cancer growth. Am J Clin Exp Urol (2014) 0.78

Re: stimulation of prostate cancer cellular proliferation and invasion by the androgen receptor co-activator ARA70. Eur Urol (2008) 0.77

Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer. Horm Cancer (2016) 0.77

Dynamic distribution of nuclear coactivator 4 during mitosis: association with mitotic apparatus and midbodies. PLoS One (2011) 0.76

Candidate genes contributing to the aggressive phenotype of mantle cell lymphoma. Acta Histochem (2010) 0.75

Iron overload and altered iron metabolism in ovarian cancer. Biol Chem (2017) 0.75

Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (2003) 100.88

Getting started with yeast. Methods Enzymol (1991) 26.67

Studies on the transformation of intact yeast cells by the LiAc/SS-DNA/PEG procedure. Yeast (1995) 13.20

Molecular biology of the androgen receptor. J Clin Oncol (2002) 5.08

Androgen receptor (AR) coregulators: an overview. Endocr Rev (2002) 4.01

Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci U S A (1996) 3.56

Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem (2004) 3.51

Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem (2001) 2.11

Nuclear receptor coactivators: multiple enzymes, multiple complexes, multiple functions. J Steroid Biochem Mol Biol (1999) 2.00

Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene (1994) 1.87

Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res (2000) 1.75

The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus. EMBO J (2002) 1.72

Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol (1999) 1.68

Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Mol Cell Endocrinol (1997) 1.62

Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer. Cancer Res (2005) 1.57

The FXXLF motif mediates androgen receptor-specific interactions with coregulators. J Biol Chem (2002) 1.57

Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. Cancer Res (1993) 1.44

Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. Am J Pathol (2002) 1.41

Androgen-receptor-interacting nuclear proteins. Biochem Soc Trans (2000) 1.38

Androgen induction of in vitro prostate cell differentiation. Cell Growth Differ (2002) 1.33

Interaction of the putative androgen receptor-specific coactivator ARA70/ELE1alpha with multiple steroid receptors and identification of an internally deleted ELE1beta isoform. Mol Endocrinol (1999) 1.25

Aberrant expression of E-cadherin and beta-catenin in human prostate cancer. Urol Oncol (2005) 1.24

ART-27, an androgen receptor coactivator regulated in prostate development and cancer. J Biol Chem (2004) 1.23

Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines. Exp Cell Res (2006) 1.22

Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res (1994) 1.22

Variation of prostate-specific antigen expression in different tumour growth patterns present in prostatectomy specimens. Urol Res (1990) 1.14

Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. J Biol Chem (2004) 1.13

Prostate stromal cell-derived hepatocyte growth factor induces invasion of prostate cancer cell line DU145 through tumor-stromal interaction. Prostate (1999) 1.07

Mechanisms of prostate tumorigenesis: roles for transcription factors Nkx3.1 and Egr1. Ann N Y Acad Sci (2005) 1.05

The cadherin cell-cell adhesion pathway in prostate cancer progression. Br J Urol (1997) 1.05

RFG (ARA70, ELE1) interacts with the human androgen receptor in a ligand-dependent fashion, but functions only weakly as a coactivator in cotransfection assays. Mol Endocrinol (1999) 1.00

Tumor-suppressive effects of neutral endopeptidase in androgen-independent prostate cancer cells. Clin Cancer Res (2001) 0.98

Domain interactions between coregulator ARA(70) and the androgen receptor (AR). Mol Endocrinol (2002) 0.95

Coregulators and chromatin remodeling in transcriptional control. Mol Carcinog (2004) 0.94

Loss of androgen receptor associated protein 70 (ARA70) expression in a subset of HER2-positive breast cancers. Breast Cancer Res Treat (2001) 0.94

Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression. Cancer (2006) 0.93

Expression of RFG/ELE1alpha/ARA70 in normal and malignant prostatic epithelial cell cultures and lines: regulation by methylation and sex steroids. Mol Carcinog (2001) 0.89

Androgen receptor coactivator ARA70alpha and ARA70beta isoform-specific antibodies: new tools for studies of expression and immunohistochemical localization. Appl Immunohistochem Mol Morphol (2008) 0.86

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85

Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature (2002) 10.96

The SCF ubiquitin ligase: insights into a molecular machine. Nat Rev Mol Cell Biol (2004) 8.21

Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell (2008) 7.65

Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26

Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res (2009) 6.15

Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer (2008) 6.10

S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science (2006) 5.94

Chromatin structure analyses identify miRNA promoters. Genes Dev (2008) 5.40

Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell (2009) 5.24

Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev (2004) 4.68

Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell (2011) 4.54

Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature (2004) 4.41

The Cdc14B-Cdh1-Plk1 axis controls the G2 DNA-damage-response checkpoint. Cell (2008) 4.04

Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci U S A (2009) 4.00

PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res (2009) 3.95

Control of the SCF(Skp2-Cks1) ubiquitin ligase by the APC/C(Cdh1) ubiquitin ligase. Nature (2004) 3.73

Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J Biol Chem (2003) 3.68

Control of meiotic and mitotic progression by the F box protein beta-Trcp1 in vivo. Dev Cell (2003) 3.62

SCFFbxl3 controls the oscillation of the circadian clock by directing the degradation of cryptochrome proteins. Science (2007) 3.59

Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature (2003) 3.54

Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med (2012) 3.52

PCNA-dependent regulation of p21 ubiquitylation and degradation via the CRL4Cdt2 ubiquitin ligase complex. Genes Dev (2008) 3.49

Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med (2011) 3.46

Effect of soy protein isolate supplementation on biochemical recurrence of prostate cancer after radical prostatectomy: a randomized trial. JAMA (2013) 3.40

Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest (2002) 3.36

Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol (2013) 3.34

Degradation of Id2 by the anaphase-promoting complex couples cell cycle exit and axonal growth. Nature (2006) 3.31

Genomic determination of the glucocorticoid response reveals unexpected mechanisms of gene regulation. Genome Res (2009) 3.30

Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell (2006) 3.16

The after-hours mutant reveals a role for Fbxl3 in determining mammalian circadian period. Science (2007) 3.05

Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer (2004) 3.03

American Idol and NIH Grant Review. Cell (2006) 3.01

SCFbetaTrCP-mediated degradation of Claspin regulates recovery from the DNA replication checkpoint response. Mol Cell (2006) 2.75

Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase. Mol Cell (2005) 2.75

Target-specific utilization of transcriptional regulatory surfaces by the glucocorticoid receptor. Proc Natl Acad Sci U S A (2003) 2.63

Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res (2008) 2.59

Mechanisms and function of substrate recruitment by F-box proteins. Nat Rev Mol Cell Biol (2013) 2.56

Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. J Clin Invest (2009) 2.55

Dishevelled promotes axon differentiation by regulating atypical protein kinase C. Nat Cell Biol (2007) 2.55

Proteasome-mediated degradation of p21 via N-terminal ubiquitinylation. Cell (2003) 2.54

Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell (2003) 2.53

Control of chromosome stability by the beta-TrCP-REST-Mad2 axis. Nature (2008) 2.46

Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res (2006) 2.42

APC/C(Cdc20) controls the ubiquitin-mediated degradation of p21 in prometaphase. Mol Cell (2007) 2.35

A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas. Genes Chromosomes Cancer (2007) 2.35

The development of common data elements for a multi-institute prostate cancer tissue bank: the Cooperative Prostate Cancer Tissue Resource (CPCTR) experience. BMC Cancer (2005) 2.35

Cellular senescence in usual type uterine leiomyoma. Fertil Steril (2009) 2.34

Specific small molecule inhibitors of Skp2-mediated p27 degradation. Chem Biol (2012) 2.34

The HECT-domain ubiquitin ligase Huwe1 controls neural differentiation and proliferation by destabilizing the N-Myc oncoprotein. Nat Cell Biol (2008) 2.32

TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol (2005) 2.29

Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem (2002) 2.29

Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol (2003) 2.27

JHDM1B/FBXL10 is a nucleolar protein that represses transcription of ribosomal RNA genes. Nature (2007) 2.20

Angiomyolipoma with minimal fat: can it be differentiated from clear cell renal cell carcinoma by using standard MR techniques? Radiology (2012) 2.18

A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med (2006) 2.16

Interface-induced superconductivity and strain-dependent spin density waves in FeSe/SrTiO3 thin films. Nat Mater (2013) 2.15

SCF(Cyclin F) controls centrosome homeostasis and mitotic fidelity through CP110 degradation. Nature (2010) 2.15

Rac1 accumulates in the nucleus during the G2 phase of the cell cycle and promotes cell division. J Cell Biol (2008) 2.08

Role of Polo-like kinase in the degradation of early mitotic inhibitor 1, a regulator of the anaphase promoting complex/cyclosome. Proc Natl Acad Sci U S A (2004) 2.05

Structural insights into the YAP and TEAD complex. Genes Dev (2010) 2.00

Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. Cell (2012) 1.98

Modulation of glucocorticoid receptor function via phosphorylation. Ann N Y Acad Sci (2004) 1.97

An informatics model for tissue banks--lessons learned from the Cooperative Prostate Cancer Tissue Resource. BMC Cancer (2006) 1.97

Optimizing low loss negative index metamaterial for visible spectrum using differential evolution. Opt Express (2011) 1.96

Deciphering the phosphorylation "code" of the glucocorticoid receptor in vivo. J Biol Chem (2002) 1.95

Dual mode of degradation of Cdc25 A phosphatase. EMBO J (2002) 1.95

APC/C- and Mad2-mediated degradation of Cdc20 during spindle checkpoint activation. Cell Cycle (2009) 1.94

USP33 regulates centrosome biogenesis via deubiquitination of the centriolar protein CP110. Nature (2013) 1.94

Diversity of 16S rRNA genes within individual prokaryotic genomes. Appl Environ Microbiol (2010) 1.93

Role of desumoylation in the development of prostate cancer. Neoplasia (2006) 1.90

KDM2A represses transcription of centromeric satellite repeats and maintains the heterochromatic state. Cell Cycle (2008) 1.90

SENP1 enhances androgen receptor-dependent transcription through desumoylation of histone deacetylase 1. Mol Cell Biol (2004) 1.89

SnapShot: F Box Proteins II. Cell (2009) 1.88

The development and deployment of Common Data Elements for tissue banks for translational research in cancer - an emerging standard based approach for the Mesothelioma Virtual Tissue Bank. BMC Cancer (2008) 1.88

MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem (2011) 1.88

Novel p27(kip1) C-terminal scatter domain mediates Rac-dependent cell migration independent of cell cycle arrest functions. Mol Cell Biol (2003) 1.85

Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-κB signalling. Nat Commun (2011) 1.84

Glucocorticoid receptor phosphorylation differentially affects target gene expression. Mol Endocrinol (2008) 1.81

Secondary Use of EHR: Data Quality Issues and Informatics Opportunities. AMIA Jt Summits Transl Sci Proc (2010) 1.81

FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature (2012) 1.79

Clinicopathologic features of rhabdomyosarcoma of gynecologic origin in adults. Am J Surg Pathol (2007) 1.79

Amplification, mutation, and sequencing of a six-letter synthetic genetic system. J Am Chem Soc (2011) 1.78

mTOR generates an auto-amplification loop by triggering the βTrCP- and CK1α-dependent degradation of DEPTOR. Mol Cell (2011) 1.78

betaTrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosis. Mol Cell (2009) 1.77

Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell (2009) 1.77

MED14 and MED1 differentially regulate target-specific gene activation by the glucocorticoid receptor. Mol Endocrinol (2005) 1.76

The tissue microarray data exchange specification: implementation by the Cooperative Prostate Cancer Tissue Resource. BMC Bioinformatics (2004) 1.74

Prostate cancer vs. post-biopsy hemorrhage: diagnosis with T2- and diffusion-weighted imaging. J Magn Reson Imaging (2010) 1.70

Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. Cancer Res (2006) 1.69

Cyclin-dependent kinase 5 differentially regulates the transcriptional activity of the glucocorticoid receptor through phosphorylation: clinical implications for the nervous system response to glucocorticoids and stress. Mol Endocrinol (2007) 1.68

Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res (2005) 1.68

Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod Pathol (2005) 1.67

Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes Dev (2008) 1.61

ETS rearrangements and prostate cancer initiation. Nature (2009) 1.58

Control of cell growth by the SCF and APC/C ubiquitin ligases. Curr Opin Cell Biol (2009) 1.55

An Rb-Skp2-p27 pathway mediates acute cell cycle inhibition by Rb and is retained in a partial-penetrance Rb mutant. Mol Cell (2004) 1.55